Hospital Injectable Products · LP-176
Atropine Injection
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-176Hospital Injectable Products
- Generic identity
- AtropineInjection
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-176
- Generic ingredient
- Atropine
- Dosage form
- Injection
- Proposed strength
- 0.6 mg/mL
- Proposed pack
- Ampoule 1 mL; carton 10 ampoules
- Portfolio category
- Hospital Injectable Products
About Atropine
Atropine is an antimuscarinic medicine that reduces selected parasympathetic effects. Injectable preparations have defined uses in acute and procedural care, including particular cardiac and poisoning contexts. Its role differs from atropine eye drops. A concentration printed in a catalogue does not establish the correct route, indication or clinical protocol for an individual emergency.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Professional selection depends on the mechanism of the patient’s condition and the treatment setting. Cardiac monitoring and access to appropriate emergency care may be required. Atropine used within a poisoning protocol is not a general antidote for all toxins, and a cardiac use cannot be assumed appropriate for every slow pulse. The external reference label illustrates ingredient-related risks and does not establish equivalent strength, packaging or local authorization for this candidate.
Important safety considerations
Tachycardia, dry mouth, blurred vision, reduced sweating, urinary retention and confusion can occur. Excessive antimuscarinic effects can produce serious toxicity, including overheating and central nervous system disturbance. Heart disease, glaucoma and obstructive urinary or gastrointestinal conditions require relevant assessment, depending on the emergency context. Children and older adults can be particularly susceptible to adverse effects. Product, concentration and route errors must be actively prevented.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The source describes a 0.6 mg/mL injectable ampoule. The exact atropine salt, strength basis, excipients and permitted routes require confirmation. Ophthalmic preparations and differently concentrated injections are not interchangeable with this presentation.
Professional preparation must follow the authorized label and local aseptic procedures. Confirm the correct container, concentration, route and expiry before use. Storage, transport, dilution compatibility and any period after opening or reconstitution require product-specific evidence; this page does not establish them.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Confirm the acute or procedural indication, patient-specific risks, other medicines and monitoring. Match the exact product and route to an authorized local protocol.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Atropine
- Dosage form / presentation
- Injection
- Catalogue strength
- 0.6 mg/mL
- Catalogue pack
- Ampoule 1 mL; carton 10 ampoules
- Portfolio category
- Hospital Injectable Products
Layer 02
Unresolved product-specific fields
- The catalogue establishes atropine injection at 0.6 mg/mL in a 1 mL ampoule but does not identify the exact salt/strength basis, authorised route, excipients or compatibility.
- Ophthalmic atropine and differently concentrated injections are separate products and are not treated as equivalent.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- DailyMed: atropine sulfate injection — external reference labelgovernment-hosted external product label
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Sterile product specification confirming exact active chemical form, concentration or vial content, container/fill, authorised route(s), excipients/preservatives and preparation/compatibility controls.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-176, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-176.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.